Newswise — December 20, 2016 – For critically ill patients with heart or lung failure that does not respond to conventional treatments, extracorporeal life support (ECLS) can provide a bridge to survival. Updated analysis of a worldwide database finds that ECLS technologies are becoming more widely available and more frequently used at centers around the world, according to a report in the ASAIO Journal, published by Wolters Kluwer.
The new update from the Extracorporeal Life Support Organization (ELSO) registry—the first since 2012—summarizes current data on ECLS submitted to the registry. Writing on behalf of the ELSO registry, Dr. Ravi Thiagarajan and colleagues state, "The ELSO registry has collected important information on ECLS use from centers worldwide and has helped understand ECLS utilization and outcomes."
Latest Data on ECLS—Use, Outcomes, and Complications Extracorporeal life support refers to the use of extracorporeal membrane oxygenation (ECMO) and other techniques to provide blood circulation and oxygenation for certain groups of critically ill patients. Like cardiopulmonary bypass during surgery, ECLS takes over the work of the heart and lung—but for a period of days or weeks, rather than just a few hours.
As of July, 2016, the ELSO registry included information on 78,397 infants, children, and adults receiving ELCS since 1989. In 2015, the last year of full data collection, ECLS was used in 7,901 patients at 310 centers worldwide. The report shows that ECLS is now being used more often in adults than in newborns with respiratory failure.
Overall, 70 percent of patients were successfully weaned off ECLS, while 58 percent survived to be discharged from the hospital. When ECLS was used for respiratory failure, the rate of survival to discharge in 74 percent for newborns (under 30 days) and 58 percent for older children and adults.
Newborns with respiratory failure remain the largest group of ECLS patients. However, the use of ECLS in this group of patients has decreased in recent years, while rates of survival to hospital discharge have decreased as well. These trends likely reflect advances in mechanical ventilation, resulting in a more critically ill group of infants being placed on ECLS.
Meanwhile, adults with respiratory failure are the fastest-growing group of ECLS patients. This trend may reflect the impact of the H1N1 influenza ("swine flu") epidemic, as well as a 2009 study (the CESAR trial) showing that ECMO improves survival in adults with severe respiratory failure.
ECLS is also used in patients with various causes of cardiac failure—overall rates of survival to hospital discharge were 42 percent for newborns, 51 percent for older children, and 41 percent for adults. As surgery to correct congenital heart defects becomes increasingly complex, the use of ECLS for cardiac support in infants and children is expected to grow.
There is also a trend toward increased use of ECLS in patients who don't respond to cardiopulmonary resuscitation. Rates of survival to hospital discharge in these "ECPR" cases remain relatively low: 41 percent for infants and children and 29 percent for adults.
Although ECLS is potentially lifesaving, the patients who need it are severely ill, and remain at high risk of complications and death. "Adverse events during the course of ECLS are common, and underscore the need for skilled ECLS management and appropriately trained ECLS personnel and teams," Dr. Thiagarajan and coauthors write.
Given the complexity of ECLS technologies and the critical illness of patients requiring this type of support, continuous data collection and analysis are essential to achieve continued progress in appropriate use and good clinical outcomes of ECLS. Dr. Thiagarajan and colleagues conclude, "The ELSO registry remains an important and valuable source of ECLS information that will continue to influence the use of ECLS."
Click here to read “Extracorporeal Life Support Organization Registry International Report 2016.”
Article: “Extracorporeal Life Support Organization Registry International Report 2016” (doi: 10.1097/MAT.0000000000000475)
###
About the JournalASAIO Journal, the official publication of ASAIO, is in the forefront of artificial organ research and development and has an Impact Factor of 2.291. On the cutting edge of innovative technology, it features peer-reviewed articles of the highest quality that describe research, development, the most recent advances in the design of artificial organ devices and findings from initial testing. Bimonthly, the ASAIO Journal features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world. To receive updates on the latest research published in ASAIO Journal, follow @asaiojournal on Twitter and like us on Facebook.
About Wolters KluwerWolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.
RSS